• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    4D Molecular Therapeutics Inc (NQ: FDMT )

    8.120 -0.160 (-1.93%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about 4D Molecular Therapeutics Inc

    < Previous 1 2 3 4 5 Next >
    4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate
    4D Molecular Therapeutics stock drops after the company shared interim data from the PRISM Phase 1/2 trial and details on its Phase 3 4FRONT study for wet AMD. The Phase 3 study comparing 4D-150 to... 
    Via Benzinga
    The Latest Analyst Ratings For 4D Molecular Therapeutics
    Via Benzinga
    FDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS for Q2 2024
    FDMT stock results show that 4D Molecular Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Peeling Back The Layers: Exploring 4D Molecular Therapeutics Through Analyst Insights
    Via Benzinga
    Assessing 4D Molecular Therapeutics: Insights From 7 Financial Analysts
    Via Benzinga
    Analyst Expectations For 4D Molecular Therapeutics's Future
    Via Benzinga
    4D Molecular Therapeutics Goes Neck To Neck With Rival, Shares New Phase 2 Data For Its Wet AMD Candidate
    4D Molecular Therapeutics reports 24-week interim data from its PRISM Phase 2 trial, showing 77% of wet AMD patients injection-free with 4D-150. The trial highlights safety and efficacy in reducing... 
    Via Benzinga
    Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
    Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform. 
    Via Benzinga
    4D Molecular Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
    Via Benzinga
    What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics
    Via Benzinga
    Why Is 4D Molecular (FDMT) Stock Up 85% Today?
    Investors in 4D Molecular Therapeutics and FDMT stock are seeing big gains today, as the stock surges 80% on positive trial results. 
    Via InvestorPlace
    Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Why Is 4D Molecular Therapeutics Stock Trading Lower On Thursday? Genetic Disease-Focused Study Data Released
    4D Molecular Therapeutics shares interim data from the 4D-710 Phase 1/2 AEROW clinical trial for cystic fibrosis lung disease. 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    FDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS, Misses Revenue for Q1 2024
    FDMT stock results show that 4D Molecular Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
    Via Benzinga
    Topics ETFs
    4D Molecular Therapeutics Outlines Pivotal Development Plans For Cystic Fibrosis, Rare Inherited Disease
    4D Molecular Therapeutics' latest advancements in CF treatment. Get insights into their 4D-710 aerosolized genetic medicine for cystic fibrosis lung disease, including Phase 1/2 AEROW trial updates and... 
    Via Benzinga
    Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today?
    Adverum Biotechnologies' Ixo-vec gene therapy for wet AMD. Preliminary LUNA Phase 2 trial data show safety, efficacy, and significant treatment burden reduction. 
    Via Benzinga
    Why 4D Molecular Therapeutics (FDMT) Stock Is Diving
    4D Molecular Therapeutics shares are trading lower by 12.7% Wednesday afternoon. The company announced pricing of an upsized underwritten public offering. 
    Via Benzinga
    4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast
    4D Molecular Therapeutics' 4D-150 Phase 2 results for wet AMD treatment. BMO Capital optimistic, target price raised to $70. 
    Via Benzinga
    Crude Oil Moves Higher; Caterpillar Posts Upbeat Earnings
    U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 200 points on Monday. The Dow traded down 0.53% to 38,450.28 while the NASDAQ fell 0.11% to 15,612.52. The... 
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS... 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Gold Moves Lower; ISM Services PMI Beats Estimates
    U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday. The Dow traded down 1.04% to 38,253.72 while the NASDAQ fell 0.86% to 15,493.97. The... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Is Eye Disease-Focused 4D Molecular Therapeutics Stock Shooting Higher Today?
    4D Molecular Therapeutics data in wet AMD treatment. Phase 2 PRISM trial shows promising results - 89% reduction in anti-VEGF injections, stable visual acuity. 
    Via Benzinga
    Estée Lauder Posts Upbeat Earnings, Joins ON Semiconductor, Tyson Foods And Other Big Stocks Moving Higher On Monday
    U.S. stocks traded lower, with the Dow Jones falling over 300 points on Monday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Dow Tumbles 150 Points; McDonald's Sales Miss Views
    U.S. stocks traded lower this morning, with the Dow Jones index falling around 150 points on Monday. Following the market opening Monday, the Dow traded down 0.41% to 38,494.03 while the NASDAQ fell... 
    Via Benzinga
    Topics Earnings Stocks
    Exposures Financial US Equities
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.